Cargando…
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
Immune checkpoint inhibitors (CI) have demonstrated clinical activity in Hodgkin Lymphoma (HL) patients relapsing after autologous stem cell transplantation (ASCT), although only 20% complete response (CR) rate was observed. The efficacy of CI is strictly related to the host immune competence, which...
Autores principales: | Guolo, Fabio, Minetto, Paola, Pesce, Silvia, Ballerini, Filippo, Clavio, Marino, Cea, Michele, Frello, Michela, Garibotto, Matteo, Greppi, Marco, Bozzo, Matteo, Miglino, Maurizio, Passannante, Monica, Marcolin, Riccardo, Tedone, Elisabetta, Colombo, Nicoletta, Mangerini, Rosa, Bo, Alessandra, Ruzzenenti, Maria Rosaria, Carlier, Paolo, Serio, Alberto, Luchetti, Silvia, Dominietto, Alida, Varaldo, Riccardo, Candiani, Simona, Agostini, Vanessa, Ravetti, Jean Louis, Del Zotto, Genny, Marcenaro, Emanuela, Lemoli, Roberto Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603402/ https://www.ncbi.nlm.nih.gov/pubmed/34804039 http://dx.doi.org/10.3389/fimmu.2021.753890 |
Ejemplares similares
-
S217: POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION
por: Guolo, Fabio, et al.
Publicado: (2023) -
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
por: Minetto, Paola, et al.
Publicado: (2020) -
Harnessing NK Cells for Cancer Treatment
por: Minetto, Paola, et al.
Publicado: (2019) -
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020) -
Harnessing Immune Response in Acute Myeloid Leukemia
por: Riva, Carola, et al.
Publicado: (2023)